Although descriptive, the present results indicate that the pharmacological modulation of thede novoceramide biosynthesis may be a promising target for the treatment of age-related pathologies as shown in preclinical models of AD [20], insulin resistance [51], and microglia-driven inflammation [52], conditions in which the ceramide build-up has been proposed to be involved in the disease onset and progression. This evidence concerns the gene INS and Alzheimer disease.